Trial Profile
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Uprosertib (Primary) ; Dabrafenib; Trametinib
- Indications Cancer; Lung cancer; Malignant melanoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2023 Planned End Date changed from 31 Dec 2022 to 6 Oct 2024.
- 14 May 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 18 Mar 2021 Planned End Date changed from 15 Feb 2021 to 31 Dec 2021.